Clinical Trials on Recurrent Gallbladder Carcinoma

Total 28513 results

National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Hilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditions

United States
National Cancer Institute (NCI)

Completed

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Stage IV Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder...

United States
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Recurrent Gallbladder Carcinoma | Metastatic Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Recurrent Intrahepatic Cholangiocarcinoma | Metastatic... and other conditions

United States
University of Southern California
National Cancer Institute (NCI); Van Andel Research Institute

Active, not recruiting

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Recurrent Hepatocellular Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular...

United States
National Cancer Institute (NCI)

Completed

Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular...

United States
National Cancer Institute (NCI)

Completed

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder | Adenocarcinoma of the Gallbladder | Adenocarcinoma With... and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular... and other conditions

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery

Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder

United States, Canada
National Cancer Institute (NCI)

Terminated

BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

Advanced Adult Primary Liver Cancer | Localized Extrahepatic Bile Duct Cancer | Localized Gallbladder Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Malignant Neoplasm | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adenocarcinoma of the Gallbladder | Adenocarcinoma of the Extrahepatic Bile Duct

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

Gastrointestinal Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder

United States
National Cancer Institute (NCI)

Terminated

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Terminated

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Pancreatic Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Stage II Gallbladder Cancer | Stage IIIA Gallbladder Cancer | Stage IIIB Gallbladder... and other conditions
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Gastrointestinal Cancer | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder... and other conditions

United States
National Cancer Institute (NCI)
Pontificia Universidad Catolica de Chile

Completed

Initial Study of Gallbladder Cancer in Chile

Gallbaldder Cancer

Chile
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices

Current Smoker | Malignant Neoplasm | Carcinoma In Situ | Primary Neoplasm | Recurrent Neoplasm

United States
All India Institute of Medical Sciences, New Delhi

Unknown

Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

Metastatic Carcinoma to the Uterine Cervix | Recurrent Carcinoma Cervix | Cervix Carcinoma Recurrent

India
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Head and Neck Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Southwest Hospital, China

Unknown

A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC

Hepatocellular Carcinoma Recurrent

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Recurrent Head and Neck Carcinoma | Recurrent Skin Carcinoma | Recurrent Salivary Gland Carcinoma | Skin Squamous Cell Carcinoma

United States
Krankenhaus Nordwest
German Research Foundation

Recruiting

Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (GAIN)

Biliary Tract Cancer | Incidental Gallbladder Carcinoma

Germany
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma

United States
University of Washington
National Cancer Institute (NCI); United States Department of Defense

Recruiting

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
University of Washington
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Tata Memorial Hospital

Unknown

Tomotherapy in Postsurgery Recurrent Carcinoma Cervix

Postsurgery Recurrent Carcinoma Cervix

India
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astex Pharmaceuticals...

Completed

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditions

United States
National Cancer Institute (NCI)

Completed

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Sarcoma

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7 | Stage III Intrahepatic Cholangiocarcinoma AJCC v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid Tumor

Canada
Remix Therapeutics

Recruiting

Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma | Recurrent Adenoid Cystic Carcinoma

United States
Hyunseok Kang, MD
NeoImmuneTech

Recruiting

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell Carcinoma

United States

Clinical Trials on Recurrent Gallbladder Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations